|NAVB -- Israel Stock|| |
ILS 49.30 2.00 4.23%
The current investor indifference towards the small price fluctuations of Navidea Biopharmaceuticals may encourage investors to take a closer look at the firm as it closed today at a share price of 47.3
in trading volume. The company executives did not add any value to Navidea Biopharmaceutica investors in February
. However, most investors can still diversify their portfolios with Navidea Biopharmaceuticals to hedge your portfolio against high-volatility market scenarios. The stock standard deviation of daily returns for 30 days (very short) investing horizon is currently 0.0. The very small Stock volatility is a good signal to investors with longer term investment horizons. This diagnostics interface makes it easy to digest most current publicly released information about Navidea Biopharmaceutica as well as get updates on important government artifacts including earning estimates, SEC corporate filings and announcements. This module also helps to analysis Navidea Biopharmaceutica price relationship with some important fundamental indicators such as market cap and management efficiency. Please see also Stocks Correlation
Navidea Biopharmaceutica Note
About 35.0% of the company shares are owned by institutional investors. The company has Price/Earnings (P/E) ratio of 197.2. Navidea Biopharmaceutica recorded loss per share of 0.1. The entity had not issued any dividends in recent years. Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. Navidea Biopharmaceuticals, Inc. was founded in 1983 and is headquartered in Dublin, Ohio. Navidea Biopharmaceutica is traded on Tel Aviv Stock Exchange in Israel. To find out more about NAVIDEA BIOPHAR contact Ricardo Gonzalez at 614-793-7500 or learn more at http://www.navidea.com.
Navidea Biopharmaceutica Alerts
|Navidea Biopharmaceutica is not yet fully synchronised with the market data|
|Navidea Biopharmaceutica has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations|
|The company reported revenue of 1.45M. Net Loss for the year was (19.16M) with profit before overhead, payroll, taxes, and interest of 1.81M. |
The company currently falls under 'Micro-Cap' category with current market capitalization of 94M.
Navidea Biopharmaceutica has return on total asset (ROA) of (56.42) %
which means that it has lost $56.42 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (212.65) %
meaning that it generated substantial loss on money invested by shareholders.
Navidea Biopharmaceutica Technical and Predictive Indicators